QIAGEN Annual Report 2005 QIAGEN Inc. 27220 Turnberry Lane Suite 200 Valencia CA 91355-1106 Phone (+1)

The Netherlands QIAGEN N.V. Spoorstraat 50 5911 KJ Venlo Phone (+31) 77-320-8400 Fax (+31) 77-320-8409

QIAGEN Benelux B.V. Spoorstraat 50 5911 KJ Venlo Phone (+31) 77-327-0757 Fax (+31) 77-327-0758

Austria QIAGEN Vertriebs GmbH Löwengasse 47/6 1030 Vienna Phone (+43) 1-710-1500 Fax (+43) 1-710-1500-10

Australia QIAGEN Pty Ltd PO Box 641 Doncaster Victoria 3108 Phone (+61) 3-9840-9800 Fax (+61) 3-9840-9840

Canada QIAGEN Inc. 2800 Argentia Road, Unit 7 Mississauga, Ontario L5N 8L2 Phone (+1) 800-572-9613 Fax (+1) 800-713-5951

Nextal Biotechnologies 1751 Richardson Street, Suite 6101 Montreal, Quebec, H3K 1G6 Phone (+1) 514-849-8057 Fax (+1) 514-849-4588

France QIAGEN S.A. 3 avenue du Canada LP 809 91974 Courtaboeuf Cedex Phone (+33) 1-60-920-920 Fax (+33) 1-60-920-925

Germany QIAGEN GmbH QIAGEN Strasse 1 40724 Hilden Phone (+49) 2103-29-0 Fax (+49) 2103-29-21777

QIAGEN Hamburg GmbH Königstrasse 4a 22767 Hamburg Phone (+49) 40-413647-00 Fax (+49) 40-413647-10

Italy QIAGEN S.p.A. Via Grosio, 10/10 20151 Milan Phone (+39) 2-33-43-04-11 Fax (+39) 2-33-43-04-26

Japan QIAGEN K.K. Forefront Tower II 13-1,Kachidoki 3 Chome Chuo-ku, Tokyo 104-0054 Phone (+81) 3-5547-0811 Fax (+81) 3-5547-0818

Malaysia QIAGEN Sdn. Bhd. Level 13, Wisma E&C No. 2 Lorong Dungun Kiri Damansara Heights 50490 Kuala Lumpur Phone (+603) 2094-5170 Fax (+603) 2094-5171

Norway QIAGEN AS Frysjaveien 40 0884 Oslo Phone (+47) 23-00-53-53 Fax (+47) 23-00-53-50

P.R. China QIAGEN China Representative Office Room 2213 POS PLAZA Century Avenue 1600 Pudong, Shanghai P.R. China Post code 200122 Phone (+86) 21-5116-2555 Fax (+86) 21-5116-2500

Tiangen Biotech (Beijing) Co., Ltd. 4th Floor, Beilu Building 35 Chengfu Road, Haidian District, Beijing 100083 Phone (+86) 10-8262-9288 Fax (+86) 10-8261-3663

PGBiotech Co., Ltd. F6, R3-B, High-Tech Industrial Park Shen Nan Avenue Shenzhen 518057 Phone (+86) 755-2650-4888 Fax (+86) 755-2673-3666

Sweden QIAGEN AB Frösundaviks Allé 15 16970 Solna Sweden Phone (+46) 8-5090-4682 Fax (+46) 8-655-2610

Switzerland QIAGEN Instruments AG Garstligweg 8 8634 Hombrechtikon Phone (+41) 55-254-21-11 Fax (+41) 55-254-21-00

United Kingdom QIAGEN Ltd. QIAGEN House Fleming Way Crawley West Sussex, RH10 9NQ Phone (+44) 1293-422-900 Fax (+44) 1293-422-922

USA QIAGEN North American Holdings, Inc. 19300 Germantown Rd Germantown MD 20874 Phone (+1) 240-686-7774 Fax (+1) 240-686-7775

QIAGEN Inc. 27220 Turnberry Lane Suite 200 Valencia CA 91355-1106 Phone (+1) 800-426-8157 Fax (+1) 800-718-2056

QIAGEN Sciences Inc. 19300 Germantown Rd Germantown MD 20874 Phone (+1) 240-686-7700 Fax (+1) 240-686-1618

www.qiagen.com

Q IA

G E

N

2 0

0 5

A N

N U

A L

R E

P O

R T

Preparing the Future

A N N U A L R E P O R T 2 0 0 5

QIAGEN

In a 2005 survey of 5,000 life science customers, QIAGEN was recognized as the most trustworthy supplier and ranked first in setting industry standards. With more than 500 products addressing all needs in preanalytical sample preparation and processing, QIAGEN provides scientists with the broadest product and technology platform for these applications in the industry. QIAGEN has built this powerful brand by continuously fueling science by providing solutions that enable complex analysis through standardized, reliable and easy-to-handle tools.

* Based on Company’s estimates.

Did you know that QIAGEN products have been used in preparing more than 850,000,000 * nucleic acid samples

QIAGEN International Contacts

Düsseldorf

Oslo

Venlo

London

Paris

Stockholm Amsterdam

Zürich

Vienna

Milan

Montreal

Germantown

Valencia

Shanghai

Tokyo

Melbourne QIAGEN Companies

QIAGEN Distributors and Importers

Kuala Lumpur

Shenzhen

Hamburg

Beijing

Toronto

The Form 20-F is an integral part of this Annual Report. It contains detailed fi nan cial information on the Company as well as other infor mation, in cluding information on the markets and risks and on QIAGEN‘s Directors, Management and Advisors. It also contains a summary of the Company’s Code of Ethics, descriptions on sec urities other than equity securities, information on controls and procedures as well as QIAGEN‘s dec laration of compliance regarding the German and the Dutch corporate governance codes.

If the Form 20-F insert is missing from this Annual Report, it can be requested from the Company or can be downloaded from the investor relations section of QIAGEN’s homepage under www.QIAGEN.com.

Consolidated Statement of Income Data

50,000

Net sales 1,000 US$

150,000

250,000

350,000

450,000

2001 2002 2003 2004 2005

+13 % 5-year CAGR

Net income 1,000 US$

5,000

20,000

35,000

50,000

65,000

2001 2002 2003 2004 2005

+24 % 5-year CAGR

0.1

0.2

0.3

0.4

0.5

Diluted earnings per share US$ PER SHARE

2001 2002 2003 2004 2005

+24 % 5-year CAGR

F IN

A N

C IA

L H

IG H

LI G

H T S

Trademarks and Disclaimers Trademarks

Our name together with our logo is registered as a trade-

mark in The Netherlands, the United States and a number

of other countries: QIAGEN®.

Other trademarks registered in the United States include,

inter alia: QIAexpress®, QIAwell®, QIAEX®, QIAprep®,

QIAamp®, QIAquick®, Oligotex®, RNeasy®, BIOROBOT®,

ENDOFREE®, R.E.A.L.®, PolyFect®, SuperFect®, DNeasy®,

UltraFect®, TurboFilter®, HotStarTaq®, EFFECTENE®, QIA®,

DyeEx®, Omniscript®, Sensiscript®, HiSpeed®, Targetene®,

TransMessenger®, MagAttract®, DirectPrep®, InhibitEX®,

DoubleTag®, QuantiScript®, UltraSens®, pAlliance®,

EverGene®, ProofStart®, FlexiGene®, QuantiTect®,

DNAprotect®, and LiquiChip®.

Registered trademarks in countries outside of the United

States include: QIAexpress®, QIAwell®, QIABRANE™,

QIAEX®, QIAprep®, QIAamp®, QIAquick®, Oligotex®,

RNeasy®, BIOROBOT®, ENDOFREE®, R.E.A.L.®,

PolyFect®, SuperFect®, DNeasy®, UltraFect®, HotStarTaq®,

EFFECTENE®, QIA®, DyeEx®, Omniscript®, Sensiscript®,

HiSpeed®, Targetene®, TransMessenger®, MagAttract®,

DirectPrep®, InhibitEX®, DoubleTag® ,QuantiScript®,

UltraSens®, ProofTaq™, pAlliance®, MinElute®, EverGene®,

ProofStart®, FlexiGene®, QuantiTect®, VARISPAN™,

RNAprotect®, DNAprotect®, LiquiChip®, CryoCell®,

LabelStar™, ROSYS™, RNAiFect™, Easylabel™ and

EasyXpress™.

In 2004 four trademark applications were fi led in Ger-

many, Countries of the European Community, Japan and

the United States of America for BioSprint, AllPrep™, and

Qproteome.

KingFisher® is a registered trademark of Thermo Electron

Corp. GeneChip® is a registered trademark of Affymetrix,

Inc.

This Annual Report may also contain trade names

or trademarks of companies other than QIAGEN.

© 2006 QIAGEN, all rights reserved.

This annual report, in addition to historical information,

contains certain forward-looking statements made pursuant

to the Private Securities Litigation Reform Act of 1995.

Such statements may involve signifi cant risks and uncer-

tainties and actual results could differ materially from those

expressed or implied herein. Please refer to the section

entitled „Risk Factors“ under Item 3 of our Form 20-F for

the year ended December 31, 2005, which accompanies

and is part of this Annual Report, for a discussion related

to forward-looking statements contained in this Annual

Report.

Registered names, trademarks, etc. used in this document,

even when not specifi cally marked as such, are not to be

considered unprotected by law.

Disclaimer

The BioRobot MDx DSP system is not available in all

countries; please inquire.

The PCR process is covered by the foreign counterparts

of U.S. Patents Nos. 4,683,202 and 4,683,195 owned by

F. Hoffmann-La Roche Ltd.

The QIAGEN BioRobot MDx DSP workstation and QIAamp

DSP kits comply with EU Directive 98/79/EC on in vitro

diagnostic medical devices. Other (non-DSP) QIAGEN

workstations and kits are intended as general-purpose

devices. No claim or representation is intended for their

use to identify any specifi c organism or for a specifi c

clinical use (diagnostic, prognostic, therapeutic, or blood

banking). It is the user’s responsibility to validate the perfor-

mance of QIAGEN non-DSP workstations and kits for any

particular use, since their performance characteristics have

not been validated for any specifi c organism. QIAGEN

non-DSP workstations and kits may be used in clinical

diagnostic laboratory systems after the laboratory has

validated their complete system as required by CLIA ‚88

regulations in the U.S. or equivalents in other countries.

The PAXgene Blood RNA System and the PAXgene Blood

DNA System ar